Skip to main content

Advertisement

SpringerLink
Log in

The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy

  • Palliative Medicine (A Jatoi, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of numerous chemotherapy drugs. CIPN negatively impacts function and quality of life during and after treatment. We will provide a review of the data describing the physical consequences of CIPN and discuss the possible long term impact on emotional well-being and quality of life.

Recent Findings

CIPN negatively affects physical function and many aspects of quality of life. Exercise interventions are likely to reduce the risk of falls associated with CIPN.

Summary

There remains a need for evidence-based interventions focused on improving symptoms, function, and quality of life in persons with CIPN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Tofthagen C, Visovsky C, Dominic S, McMillan S. Neuropathic symptoms, physical and emotional well-being, and quality of life at the end of life. Support Care Cancer. 2019.

  2. • McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Menant J, et al. Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments. J Natl Compr Cancer Netw. 2019;17(8):949–55 Reports on numerous functional and balance deficits and proposes a risk based screening model for identifying persons at risk of falls and functional decline.

    Article  Google Scholar 

  3. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016;157(3):560–8.

    Article  CAS  PubMed  Google Scholar 

  4. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.

    Article  PubMed  Google Scholar 

  5. Tofthagen C, Kip KE, Passmore D, Loy I, Berry DL. Usability and acceptability of a web-based program for chemotherapy-induced peripheral neuropathy. Comput Inform Nurs. 2016;34(7):322–9.

    Article  PubMed  Google Scholar 

  6. Kim JH, Dougherty PM, Abdi S. Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. Gynecol Oncol. 2015;136(3):453–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Holst-Wolf J, Tseng YT, Konczak J. The Minnesota haptic function test. Front Psychol. 2019;10:818.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Almadrones LA, Arcot R. Patient guide to peripheral neuropathy. Oncol Nurs Forum. 1999;26(8):1359–60.

    CAS  PubMed  Google Scholar 

  9. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013;21(7):2059–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012;20(3):583–9.

    Article  PubMed  Google Scholar 

  12. • Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604–12 A comparison of functional outcomes in long term breast cancer survivors. Demonstrates sustained functional deficits related to CIPN.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med. 2010;13(11):1389–91.

    Article  PubMed  Google Scholar 

  14. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010;14(3):E22–8.

    Article  PubMed  Google Scholar 

  15. • Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6). Literature review focusing on mechanistic research findings in CIPN. Recommended for anyone who wants to increase their understanding of how each class of neurotoxic agents cause CIPN.

    Article  PubMed Central  CAS  Google Scholar 

  16. Park JH, Chae J, Roh K, Kil EJ, Lee M, Auh CK, et al. Oxaliplatin-induced peripheral neuropathy via TRPA1 stimulation in mice dorsal root ganglion is correlated with aluminum accumulation. PLoS One. 2015;10(4):e0124875.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain. 2012;13(3):276–84.

    Article  PubMed  CAS  Google Scholar 

  18. Liu F, Huang J, Liu Z. Vincristine impairs microtubules and causes neurotoxicity in cerebral organoids. Neuroscience. 2019;404:530–40.

    Article  CAS  PubMed  Google Scholar 

  19. Cairns BE, Arendt-Nielsen L, Sacerdote P. Perspectives in pain research 2014: Neuroinflammation and glial cell activation: the cause of transition from acute to chronic pain? Scand J Pain. 2015;6(1):3–6.

    Article  PubMed  Google Scholar 

  20. Zheng H, Xiao G, Bennett G. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol. 2012;238(2):225–34.

    Article  CAS  PubMed  Google Scholar 

  21. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):e01312.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wong ML, Cooper BA, Paul SM, Abrams G, Topp K, Kober KM, et al. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors. Support Care Cancer. 2019;27(10):3905–12.

    Article  PubMed  Google Scholar 

  23. • Petrovchich I, Kober KM, Wagner L, Paul SM, Abrams G, Chesney MA, et al. Deleterious effects of higher body mass index on subjective and objective measures of chemotherapy-induced peripheral neuropathy in cancer survivors. J Pain Symptom Manag. 2019;58(2):252–63. Demonstrates relationships between higher BMI and increased pain, more postural instability among cancer survivors with CIPN.

    Article  PubMed  Google Scholar 

  24. Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer. 2019;27(10):3729–37.

    Article  PubMed  Google Scholar 

  25. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25(4):316–20.

    Article  PubMed  Google Scholar 

  26. Sy A, Cheng J, Cooper R, Mueller L. Heterozygosity for CMT type 4 predicts a severe vincristine-induced polyneuropathy phenotype: a case report and review of literature. J Pediatr Hematol Oncol. 2019;41(1):e41–e3.

    Article  PubMed  Google Scholar 

  27. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013;21(5):1313–9.

    Article  PubMed  Google Scholar 

  28. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.

    Article  CAS  PubMed  Google Scholar 

  29. • Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care. 2017;26(2). Demonstrates increased reponse to duloxetine among persons with higher emotional well-being.

    Article  Google Scholar 

  30. Nho JH, Reul Kim S, Nam JH. Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy. Eur J Oncol Nurs. 2017;30:8–14.

    Article  PubMed  Google Scholar 

  31. Knoerl R, Chornoby Z, Smith EML. Estimating the frequency, severity, and clustering of SPADE symptoms in chronic painful chemotherapy-induced peripheral neuropathy. Pain Manag Nurs. 2018;19(4):354–65.

    Article  PubMed  Google Scholar 

  32. Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007;56(5):323–31.

    Article  PubMed  Google Scholar 

  33. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (Oxf Engl). 2005;41(8):1135–9.

    Article  CAS  Google Scholar 

  34. Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, et al. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Support Care Cancer. 2019;27(12):4753–62.

    Article  PubMed  Google Scholar 

  35. • Tabata A, Kanai M, Horimatsu T, Tsuboyama T, Matsushima K, Kato T. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study. Support Care Cancer. 2018;26(7):2397–405 Identified reduced sensation in the hands after a single cycle of oxaliplatin. Highlights the need for early intervention.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164(1):69–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zanville NR, Nudelman KN, Smith DJ, Von Ah D, McDonald BC, Champion VL, et al. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer. 2016;24(11):4779–89.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer. 2012;118(8 Suppl):2250–60.

    Article  PubMed  Google Scholar 

  39. Stubblefield MD. The underutilization of rehabilitation to treat physical impairments in breast cancer survivors. PM R. 2017;9(9s2):S317–s23.

    Article  PubMed  Google Scholar 

  40. Cheville AL, Dose AM, Basford JR, Rhudy LM. Insights into the reluctance of patients with late-stage cancer to adopt exercise as a means to reduce their symptoms and improve their function. J Pain Symptom Manag. 2012;44(1):84–94.

    Article  Google Scholar 

  41. Cheville AL, Troxel AB, Basford JR, Kornblith AB. Prevalence and treatment patterns of physical impairments in patients with metastatic breast cancer. J Clin Oncol. 2008;26(16):2621–9.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Komatsu H, Yagasaki K, Komatsu Y, Yamauchi H, Yamauchi T, Shimokawa T, et al. Falls and functional impairments in breast cancer patients with chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs. 2019;6(3):253–60.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kneis S, Wehrle A, Muller J, Maurer C, Ihorst G, Gollhofer A, et al. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer. 2019;19(1):414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B. Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Gerontology. 2016;62(5):553–63.

    Article  PubMed  Google Scholar 

  46. Vollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzenstein S, Rocken C, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. J Cancer Res Clin Oncol. 2018;144(9):1785–92.

    Article  PubMed  Google Scholar 

  47. Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018;26(2):615–24.

    Article  PubMed  Google Scholar 

  48. Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019;1:Cd012424.

    PubMed  Google Scholar 

  49. Hermanns M, Haas BK, Rath L, Murley B, Arce-Esquivel AA, Ballard JE, et al. Impact of tai chi on peripheral neuropathy revisited: a mixed-methods study. Gerontol Geriatr Med. 2018;4:2333721418819532.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, Di Blasio A, et al. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. Crit Rev Oncol Hematol. 2018;121:90–100.

    Article  PubMed  Google Scholar 

  51. Fernandes J, Kumar S. Effect of lower limb closed kinematic chain exercises on balance in patients with chemotherapy-induced peripheral neuropathy: a pilot study. Int J Rehabil Res. 2016;39(4):368–71.

    Article  PubMed  Google Scholar 

  52. Mizrahi D, Broderick C, Friedlander M, Ryan M, Harrison M, Pumpa K, et al. An exercise intervention during chemotherapy for women with recurrent ovarian cancer: a feasibility study. Int J Gynecol Cancer. 2015;25(6):985–92.

    Article  PubMed  Google Scholar 

  53. Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014;25(2):493–9.

    Article  CAS  PubMed  Google Scholar 

  54. Wonders KY, Whisler G, Loy H, Holt B, Bohachek K, Wise R. Ten weeks of home-based exercise attenuates symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. Health Psychol Res. 2013;1(3):e28.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, et al. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: a pilot study. Cancer. 2017;123(11):1989–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Streckmann F, Lehmann HC, Balke M, Schenk A, Oberste M, Heller A, et al. Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial. Support Care Cancer. 2019;27(7):2471–8.

    Article  PubMed  Google Scholar 

  57. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support care cancer. 2013;21(12):3307–13.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, Albrecht TL, Schwartz AG. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer. 2019;125(2):269–77.

    Article  CAS  PubMed  Google Scholar 

  59. Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–7.

    Article  PubMed  Google Scholar 

  60. Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636–41.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Tofthagen C, Visovsky C, Eckelman E, Clatterbuck B, Leggatt M, Buck H. Starting a nurse-led clinic for patients with peripheral neuropathy. Nursing. 2018;48(8):39–42.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, 32224, USA

    Cindy S. Tofthagen

  2. Mayo Clinic, 200 First Street, S.W., Rochester, MN, 55905, USA

    Andrea L. Cheville & Charles L. Loprinzi

Authors
  1. Cindy S. Tofthagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea L. Cheville
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles L. Loprinzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cindy S. Tofthagen.

Ethics declarations

Conflict of Interest

Cindy S. Tofthagen declares that she has no conflict of interest.

Andrea L. Cheville declares that she has no conflict of interest.

Charles L. Loprinzi has received compensation from PledPharma, Disarm Therapeutics, Asahi Kasei, Metys Pharmaceuticals, OnQuality, and Mitsubishi Tanabe for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not directly report the results of any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Palliative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tofthagen, C.S., Cheville, A.L. & Loprinzi, C.L. The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy. Curr Oncol Rep 22, 50 (2020). https://doi.org/10.1007/s11912-020-00903-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-00903-0

Keywords

Search

Navigation